Retinal Disease
Evidence-Based Approaches to Diagnose, Treat, and Manage Patients With Retinal Diseases: Summaries of Clinical Trials
This activity is supported by independent medical education grants from Alcon Vision, LLC; Genentech, a member of the Roche Group; IVERIC bio, Inc., an Astellas company; Ocuphire Pharma; Outlook Therapeutics; Regeneron Pharmaceuticals, Inc.; and REGENXBIO Inc.
Study shows efficacy of gene therapy in preschool children with LCA2
ROME — Voretigene neparvovec proved successful as a treatment for Leber congenital amaurosis 2 in preschool children, as shown by a study presented at the FLORetina-ICOOR meeting.
Real World Retina: Challenges in the Management of Retinal Diseases—Focus on RVO and nAMD
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.
Advances in Neovascular Retinal Disease: A Case-Based, Data-Driven Guide to Treatment
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
Patients with DME achieve long-term clinical improvement with intravitreal aflibercept
Patients with diabetic macular edema treated with intravitreal aflibercept for up to 24 months achieved functional and anatomical improvements, even with reduced injection frequency, according to study results in Ophthalmology and Therapy.
Ora, BlindCAN Film Festival launch Blind Canvas Project, create art inspired by blindness
Ora Inc. has collaborated with BlindCAN Film Festival to launch the Blind Canvas Project, which combines storytelling with artificial intelligence to create art celebrating the lives of individuals with visual impairment.
VIDEO: Optogenetic therapy shows promise in advanced retinitis pigmentosa
In this Healio Video Perspective, SriniVas R. Sadda, MD, discusses his paper on Nanoscope’s MCO-010 optogenetic therapy in advanced retinitis pigmentosa, which was presented at the Euretina congress in Amsterdam.
Significant investments will continue to advance retinal disease field
The intravitreal injection of an anti-VEGF, a corticosteroid or a complement inhibitor for the treatment of potentially blinding retinal disease is today the most common procedure performed by an ophthalmologist.
Great Debates in Neovascular Retinal Disease: What Do the Data Really Tell Us About Treatment?
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
Kiora partners with Choroideremia Research Foundation on new treatment for retinal disease
Koira Pharmaceuticals, in a new partnership with the Choroideremia Research Foundation, plans to accelerate its development of KIO-301, a treatment for the rare retinal disease choroideremia.